TL1A-Ig and IL-2LD treatment expands tissue-resident Tregs and restrains alloreactive T-cell–driven damage in GVHD target organs. Professional illustration by Patrick Lane, ScEYEnce Studios.

TL1A-Ig and IL-2LD treatment expands tissue-resident Tregs and restrains alloreactive T-cell–driven damage in GVHD target organs. Professional illustration by Patrick Lane, ScEYEnce Studios.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal